Release Date: September 12, 2025
Expiration Date: September 12, 2026
Activity Overview
Prostate cancer continues to pose substantial clinical challenges, with increasing incidence and mortality rates in the United States. While PSMA-directed radioligand therapy (RLT) and advanced imaging technologies have transformed the diagnosis and treatment of metastatic prostate cancer, knowledge gaps persist regarding optimal use, patient selection, sequencing, and integration into multidisciplinary care. Additionally, disparities in access and implementation across care settings underscore the urgent need for clinician education.
To address these unmet needs, PER® has developed this online activity that features 4 concise modules with expert video interviews. Topics will span PSMA imaging interpretation, the science and clinical application of RLT, patient selection and toxicity management, and strategies to expand equitable access through multidisciplinary care.
Target Audience
BURST CME™ Activity 1—Imaging Matters: Decoding PSMA PET for Better Decision-Making
This activity is directed toward medical oncologists, urologists, nuclear medicine physicians, radiologists, and radiation oncologists.
BURST CME™ Activity 2—Radioligand Therapy 101: The Science Behind the Strategy
This activity is directed toward nuclear medicine physicians, medical oncologists, radiation oncologists, and urologists.
BURST CME™ Activity 3—Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified
This activity is directed toward medical oncologists, radiation oncologists, and urologists.
BURST CME™ Activity 4—Working Together: Optimizing Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care
This activity is directed toward medical oncologists, urologists, radiation oncologists, nuclear medicine physicians, advanced practice providers, nurses, nurse navigators, and palliative care specialists.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
BURST CME™ Activity 1—Imaging Matters: Decoding PSMA PET for Better Decision-Making
- Determine the role of PSMA-based PET/CT scans as a key diagnostic and prognostic tool in prostate cancer
- Discuss key elements and guidelines for PSMA PET/CT interpretation in clinical practice to support accurate clinical decision-making
BURST CME™ Activity 2—Radioligand Therapy 101: The Science Behind the Strategy
- Discuss key elements and guidelines for PSMA PET/CT interpretation in clinical practice to support accurate clinical decision-making
- Assess the mechanistic and clinical rationale supporting the role of PSMA-targeting radioligand therapy in the management of patients with metastatic prostate cancer
BURST CME™ Activity 3—Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified
- Integrate PSMA-directed radioligand therapy in the management of patients with mCRPC based on guideline recommendations and clinical trial evidence
- Develop best practices for identification and management of treatment-related toxicities in patients with mCRPC being treated with PSMA-directed radioligand therapy
BURST CME™ Activity 4—Working Together: Optimizing Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care
- Identify barriers to receiving PSMA-directed radioligand therapy and strategies to expand access in the community setting.
- Devise strategies to overcome disparities in care and ensure equitable access to novel radioligand therapies in patients with mCRPC.
- Incorporate biomarker and imaging-based tools to guide multidisciplinary care and optimize outcomes with PSMA-targeted radioligand therapy
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here